Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Issues FY 2024 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) updated its FY 2024 earnings guidance on Tuesday. The company provided EPS guidance of 5.610-6.045 for the period. The company issued revenue guidance of $51.7 billion-$53.9 billion.

Bayer Aktiengesellschaft Trading Down 0.3 %

Bayer Aktiengesellschaft stock opened at $6.45 on Tuesday. The stock has a 50-day moving average price of $7.48 and a 200 day moving average price of $7.45. Bayer Aktiengesellschaft has a 52 week low of $6.39 and a 52 week high of $11.33. The company has a current ratio of 1.27, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04.

Analysts Set New Price Targets

Separately, Bank of America raised shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th. One equities research analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.